| abstract |
In one aspect, the present disclosure discloses asthma, allergic conjunctivitis, allergic dermatitis, allergic esophagitis by administration of at least one CSF1R inhibitor and, optionally, an additional therapeutic agent, an anti-inflammatory agent and / or a respiratory agent. , Allergic rhinitis, allergen-specific serum IgE production, allergic lung and airway inflammation, and diseases characterized by allergic inflammation including, but not limited to, airway hyperresponsiveness (AHR) with minimal adverse pulmonary reactions. Or related to how to treat the condition. In some embodiments, a disclosed CSF1R inhibitor useful for treatments characterized by allergic inflammation can be administered using the disclosed pharmaceutical composition. This summary is intended as a scanning tool intended for searching in a particular technical area and is not intended to limit this disclosure. [Selection diagram] FIG. 9 |